IMF, Medscape Oncology Offer Medical Education Series on Continuous Treatment in Myeloma

IMF, Medscape Oncology Offer Medical Education Series on Continuous Treatment in Myeloma
0
(0)

In partnership with Medscape Oncology, the International Myeloma Foundation (IMF) is offering a professional education series on continuous treatment in multiple myeloma, the foundation announced in a press release.

Called “Everything You Need to Know About Continuous Treatment in Multiple Myeloma,” the series of online educational courses is targeted at hematology and oncology specialists, pharmacists and nurses.

The aim is to make clinicians who care for multiple myeloma patients more knowledgeable in areas including maintenance therapy, treatment for transplant-ineligible patients, and management of adverse treatment events. The subject is timely since there is increasing evidence of the benefit of long-term, continuous treatment — as opposed to fixed-duration therapy — in new multiple myeloma patients.

Moderated by Brian G.M. Durie, MD, a multiple myeloma specialist and the IMF board chairman, the continuing medical education (CME) credit series covers a wide range of topics. These include the role of continuous therapy in transplant-ineligible patients, the role of consolidation and maintenance therapy after transplant, best practices for identifying appropriate maintenance therapy for high-risk patients, determining the optimal length of maintenance therapy, management of adverse events in maintenance therapy, and future directions in continuous treatment.

It’s expected that, after finishing the series, participants will have learned more about the available therapy options — including treatment duration — for post-autologous stem cell transplant patients. Autologous stem cell transplants use healthy blood stem cells from patients to replace their own individual diseased or damaged bone marrow. Those completing the course also will be informed of the best practices for optimized patient care, communication, and coordination.

The organizers say participants also should be better able to choose the best therapy for each newly diagnosed transplant-ineligible patient. They also will know what to watch for, and how to identify and treat common treatment-related adverse events in patients receiving consolidation or maintenance therapy.

Panelists include the following myeloma specialists:

Visit this site to register.

With 525,000 members in 140 countries, the 30-year-old IMF is the largest foundation focused specifically on multiple myeloma. It has conducted more than 250 educational seminars globally.

In addition to free CME, Medscape Oncology provides breaking medical news plus information about medicine, diseases, and procedures. Medscape, which is presenting the multiple myeloma series, recently hosted a CME series on current treatments and approaches in relapsed and refractory multiple myeloma.

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Total Posts: 145
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
×
Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Latest Posts
  • Myeloma Action Month, March
  • Takeda app
  • IMF, Medscape Oncology education series
  • Patagonia trip

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?